{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T20:58:31Z","timestamp":1781557111143,"version":"3.54.5"},"reference-count":40,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Study Design:<\/jats:title>\n                    <jats:p>Prospective open-label trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The objective of this study was to determine whether buspirone showed preliminary evidence of effectiveness, safety, and tolerability in individuals with Williams syndrome (WS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is a 16-week, prospective, flexibly dosed, open-label trial of buspirone in 20 individuals with WS aged 5\u201365 years. The primary outcome measure was the Pediatric Anxiety Rating Scale (PARS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Buspirone use (mean dose, 22.6 mg per day) was associated with a reduction in anxiety severity, with Cohen\u2019s\n                      <jats:italic toggle=\"yes\">d<\/jats:italic>\n                      estimate of \u22124.02 for the PARS. All 18 participants who completed the study received the Clinical Global Impression-Improvement subscale score for anxiety of \u201cmuch improved\u201d or \u201cvery much improved.\u201d No serious or severe adverse events occurred during the trial, and no participants discontinued the study due to adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Buspirone was safe and well tolerated. It was also associated with a reduction in anxiety severity. Given these findings, a double-blind, placebo-controlled study of buspirone in WS is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2024.0124","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T03:23:32Z","timestamp":1734405812000},"page":"222-230","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["A Prospective Open-Label Trial of Buspirone for the Treatment of Anxiety in Williams Syndrome"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8026-6970","authenticated-orcid":false,"given":"Robyn P.","family":"Thom","sequence":"first","affiliation":[{"name":"Lurie Center for Autism, Lexington, MA, USA."},{"name":"Massachusetts General Hospital, Boston, MA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Renzi","sequence":"additional","affiliation":[{"name":"Lurie Center for Autism, Lexington, MA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Pecukonis","sequence":"additional","affiliation":[{"name":"Lurie Center for Autism, Lexington, MA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Mullett","sequence":"additional","affiliation":[{"name":"Lurie Center for Autism, Lexington, MA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Ravichandran","sequence":"additional","affiliation":[{"name":"Lurie Center for Autism, Lexington, MA, USA."},{"name":"Massachusetts General Hospital, Boston, MA, USA."},{"name":"McLean Hospital, Belmont, MA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"McDougle","sequence":"additional","affiliation":[{"name":"Lurie Center for Autism, Lexington, MA, USA."},{"name":"Massachusetts General Hospital, Boston, MA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"issue":"5","key":"e_1_3_4_2_1","first-page":"492","article-title":"Psychometric characteristics of the aberrant behavior checklist","volume":"89","author":"Aman M","year":"1985","unstructured":"Aman M, , Singh N, , Stewart A, et al. Psychometric characteristics of the aberrant behavior checklist. Am J Ment Defic, 1985; 89(5):492\u2013502.","journal-title":"Am J Ment Defic"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/YPG.0000000000000218"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1162\/089892900561959"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145712000661"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199910000-00011"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199006001-00008"},{"key":"e_1_3_4_8_1","unstructured":"Bristol-Myers Squibb Company. Buspar. 2010."},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.V59N0203"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(89)90047-4"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0021"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.172.3.273"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/87565641.2003.9651896"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1352\/0895-8017(2001)106<0073:LCOBAE>2.0.CO;2"},{"issue":"12","key":"e_1_3_4_15_1","first-page":"103","article-title":"A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder","volume":"43","author":"Feighner JP","year":"1982","unstructured":"Feighner JP, , Merideth CH, , Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry, 1982; 43(12 Pt 2):103\u2013108.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.177"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1352\/1944-7558-120.4.273"},{"key":"e_1_3_4_18_1","unstructured":"Gadow K Sprafkin J. Adolescent Symptom Inventory 4: Screening Manual1997."},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.31247"},{"key":"e_1_3_4_20_1","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976","unstructured":"Guy W. ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health: Washington, DC; 1976."},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/DBP.0000000000000970"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003934"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00276-z"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.30344"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2012.06.006"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.30263"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12671-012-0178-2"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-017-3357-0"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2016.08.017"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674378903400804"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-013-1984-7"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200209000-00006"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-016-2909-z"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2308678"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1089\/CAP.2017.0060"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/088307380201700406"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpra.2022.02.025"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-019-04301-9"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1867535"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.30259"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/FPSYG.2023.1098449"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2024.0124","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2024.0124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2024.0124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T20:46:04Z","timestamp":1781556364000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2024.0124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1089\/cap.2024.0124"],"URL":"https:\/\/doi.org\/10.1089\/cap.2024.0124","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]}}}